Retrospective analysis compared outcomes in non-clear cell RCC and clear cell RCC patients, indicating significant survival differences.
Key Points
Patients with non-clear cell RCC have significantly shorter overall survival compared to clear cell RCC.
The median overall survival was 27.8 months for non-clear cell RCC vs. 62.8 months for clear cell RCC.
Among those treated with immune checkpoint inhibitor plus immune checkpoint inhibitor, non-clear cell RCC showed a median overall survival of only 23.5 months.
Careful indication evaluation is crucial when considering combination immunotherapy for patients with non-clear cell RCC.